NASDAQ:HTBX - Heat Biologics Stock Price, Forecast & News

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Heat Biologics's stock reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

Heat Biologics Inc (NASDAQ:HTBX) released its quarterly earnings data on Friday, November, 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16). The biopharmaceutical company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.91 million. Heat Biologics had a negative net margin of 695.62% and a negative return on equity of 88.07%. View Heat Biologics' Earnings History.

Heat Biologics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Heat Biologics.

2 brokers have issued twelve-month price objectives for Heat Biologics' shares. Their forecasts range from $6.00 to $8.00. On average, they expect Heat Biologics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 2,676.7% from the stock's current price. View Analyst Price Targets for Heat Biologics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.

News headlines about HTBX stock have been trending very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Heat Biologics earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the near term. View News Stories for Heat Biologics.

Heat Biologics saw a decline in short interest in January. As of January 15th, there was short interest totalling 469,500 shares, a decline of 17.8% from the December 31st total of 571,400 shares. Based on an average trading volume of 384,800 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.5% of the shares of the company are sold short. View Heat Biologics' Current Options Chain.

Some companies that are related to Heat Biologics include Acer Therapeutics (ACER), PLx Pharma (PLXP), Moleculin Biotech (MBRX), Jaguar Health (JAGX), Iterum Therapeutics (ITRM), Pulmatrix (PULM), Citius Pharmaceuticals (CTXR), Evoke Pharma (EVOK), RegeneRx Biopharmaceuticals (RGRX), IntelGenx Technologies (IGXT), Celsion (CLSN), Vistagen Therapeutics (VTGN), Alimera Sciences (ALIM), Seelos Therapeutics (SEEL) and Unum Therapeutics (UMRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Frontier Communications (FTR), Palatin Technologies (PTN), Alibaba Group (BABA), Opko Health (OPK), Juno Therapeutics (JUNO), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Sophiris Bio (SPHS), Gevo (GEVO) and Albireo Pharma (ALBO).

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HTBX stock can currently be purchased for approximately $0.25.

Heat Biologics has a market capitalization of $9.43 million and generates $5.79 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Heat Biologics employs 30 workers across the globe.View Additional Information About Heat Biologics.

The official website for Heat Biologics is http://www.heatbio.com/.

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]